Effectiveness of Ezetimibe in NAFLD patients with hyperlipidemia
Not Applicable
- Conditions
- on-alcholic fatty liver disease
- Registration Number
- JPRN-UMIN000003932
- Lead Sponsor
- Department of Hepatology, Osaka City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patient with allergy for ezetimibe 2 The following patients with grave hepatic dysfunction when use ezetimibe together with statin a)acute exacerbation of acute hepatitis , chronic hepatitis b)cirrhosis , hepatoma , choloplania(child B or more) 3 Pregnancy , women who may possibly be of pregnant 4 Patients with a history of arteriosclerotic disease 5 Patients with secondary hyperlipidemia, drug-induced dyslipidemia 6 Patients who judged that examination doctor in charge is improper
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Before and after 6 months of Ezetimibe (10mg/day) to NAFLD patients. We assessed Liver tranceminases and lipid levels.
- Secondary Outcome Measures
Name Time Method